<DOC>
	<DOCNO>NCT02602314</DOCNO>
	<brief_summary>The study investigate newly diagnose CP-CML patient efficacy NIL frontline therapy v IM follow switch NIL case absence optimal response define ELN criterion .</brief_summary>
	<brief_title>Sustained Treatment-free Remission BCR-ABL+ Chronic Myeloid Leukemia</brief_title>
	<detailed_description>This prospective , interventional , randomize , two arm , phase IV study evaluate depth molecular response rate treatment free remission rate newly diagnose CP-CML patient treat NIL IM follow switch NIL absence optimal response ( define accord ELN 2013 criterion ) per clinical practice . The enrolled patient randomize 1:1 NIL IM . Patients stratify accord Sokal risk score high versus intermediate/low risk group . Newly diagnose patient treat accord register dose NIL IM frontline chronic phase CML ( 300 mg BID 400 mg OAD , respectively ) . The patient intolerant IM patient without optimal response IM 3 month , 6 month , 12 month ( except patient progression accelerate blastic phase ) switch NIL second line . The absence optimal response define least one follow ELN criterion : ) Absence Complete Hematologic Response 3 month thereafter ; b ) Absence Partial Cytogenetic Response ( &gt; 35 % Ph+ metaphases ) 3 month ; c ) BCR-ABL transcript level &gt; 10 % accord IS 3 month ; ) Absence Complete Cytogenetic Response ( &gt; 1 % Ph+ metaphases ) 6 month ; e ) BCR-ABL transcript level &gt; 1 % accord IS 6 month ; f ) Absence Major Molecular Response ( MR3.0 , transcript level &gt; 0.1 % accord IS ) 12 month . Treatment choice patient progression advance disease phase IM patient intolerant resistant ( include progression advanced phase ) NIL principal investigator participate Center . However , information concern course outcome patient collect record least 5 year , could enrol investigational study promote GIMEMA sponsor . After induction deep molecular remission phase therapy , i.e . first two year study , residual disease closely monitor ( quarterly ) Q-PCR assay . All patient obtain reduction great 4.0 log residual disease ( MR4.0 ) within first three year treatment , maintain level response subsequent test end fourth year therapy qualify discontinuation phase study . Therefore , patient MR4.0 four-year period TKI treatment , must include final part least one year maintain MR4.0 , define 12-month period MR4.0 never lose 4 consecutive MRD analyse three-monthly interval , enter treatment free remission ( TFR ) phase study . In case loss MR3.0 , last assume TKI resume dose . All patient , include match criterion discontinuation TKI treatment , continue assign treatment follow 5 year , start date enrolment .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients confirm diagnosis BCR/ABL+ CML chronic phase Documented chronic phase CML must meet following criterion : &lt; 15 % blast peripheral blood &lt; 30 % blast plus promyelocytes peripheral blood &lt; 20 % basophils peripheral blood 100 x 109/L ( ≥ 100,000/mm3 ) platelet Age ≥18 ECOG performance status 02 Evidence typical BCRABL transcript amenable standardized RQPCR Adequate end organ function define : Total bilirubin &lt; 1.5 x ULN ( ULN = upper limit normal local institution lab ) . Does apply patient isolated hyperbilirubinemia ( e.g. , Gilbert 's disease ) grade &lt; 3 SGOT ( AST ) SGPT ( ALT ) ≤ 3 x ULN Serum amylase lipase ≤ 2 x ULN Alkaline phosphatase ≤ 2.5 x ULN Serum creatinine &lt; 1.5 x ULN Having complete QoL baseline evaluation ( i.e. , randomization ) Written informed consent prior study procedure . Expression atypical BCRABL transcript , instead classical P210encoding type e13a2 e14a2 junction screening . Previous treatment BCRABL inhibitor period longer 1 month . Previous anticancer agent ( hydroxyurea , anagrelide , interferon ) CML time longer three month . Poorly control diabetes mellitus ( define HbA1c &gt; 8 % ) . Prior documented history coronary heart disease , include myocardial infarction , coronary bypass , coronary stent , symptomatic angina : LVEF &lt; 45 % institutional low limit normal range ( whichever ishigher ) Complete leave bundle branch block Right bundle branch block plus leave anterior posterior hemiblock Use ventricularpaced pacemaker Congenital long QT syndrome know family history long QT syndrome History presence clinically significant ventricular atrial tachyarrhythmias Atrial fibrillation flutter Clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTc &gt; 450 msec average three serial screen ECGs ( use QTcF formula ) . If QTcF &gt; 450 msec electrolyte within normal range , electrolyte correct patient retested History clinical sign myocardial infarction within 12 month study entry History unstable angina within 12 month study entry Other clinically significant heart disease ( e.g . congestive heart failure ) Uncontrolled hypertension heart disease . History peripheral arterial occlusive disease . History acute pancreatitis within 12 month study entry , past medical history chronic pancreatitis . Patients actively receive therapy strong CYP3A4 inhibitor and/or inducer either discontinue switched different medication prior start study drug . Patients currently receive treatment medication potential prolong QT interval either safely discontinue switch different medication prior start study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>Nilotinib</keyword>
	<keyword>Imatinib</keyword>
</DOC>